Rationale for anti-OX40 cancer immunotherapy.


Immune checkpoint blockade with antagonistic monoclonal antibodies (mAbs) targeting B7 immunoglobulin superfamily molecules (CTLA-4, PD-1, and PD-L1) generate long lasting anti-tumour immune responses translating into clinical benefit across many cancer types. However, many patients are primarily resistant to immune checkpoint blockade -based monotherapy… (More)
DOI: 10.1016/j.ejca.2015.08.021


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.